AbbVie struck a $2.54 billion bispecific collaboration with DISCO Pharmaceuticals, adding an AND-gated strategy designed to restrict binding to tumor cells that co-express a matched pair of antigens. Once DISCO completes agreed research activities, AbbVie gets an option to exclusively license selected programs for further development. The approach is built on DISCOtech, DISCO’s surfaceome mapping platform for identifying tumor-selective target pairs. The company says the dual-antigen logic may widen addressable space while reducing on-target, off-tumor toxicity—an ongoing challenge in solid tumor targeting. For AbbVie, the pact continues a heavy external innovation slate, following prior R&D investments and acquisitions announced this year, signaling intensified interest in next-generation precision oncology platforms.